• All
  • Financials
  • Insiders
Webull provides the latest Prometheus Biosciences, Inc. (RXDX) stock and general news. This information may help you make smarter investment decisions.
About RXDX
Prometheus Biosciences, Inc. is a biotechnology company. The Company is engaged in the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD). Its precision medicine platform Prometheus360, which includes gastrointestinal (GI) bioinformatics databases, to identify therapeutic targets and develop therapeutic candidates to engage the targets. The Company's product pipeline includes PRA023, PR600, PR300, PR1800 and PR2100. Its lead product candidate PRA023, is an IgG1 humanized monoclonal antibody (mAb) designed to target both inflammation and fibrosis associated with IBD. It has focused on developing PRA023 for the treatment of UC and Crohn’s disease (CD).